Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-05-09
2010-12-28
Anderson, James D (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S408000, C514S423000, C514S693000, C514S706000, C514S315000, C514S700000, C514S715000
Reexamination Certificate
active
07858611
ABSTRACT:
The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes compositions and methods based on modulation angiotensin activity to stimulate or activate the formation of new nerve cells.
REFERENCES:
patent: 3454554 (1969-07-01), Biel et al.
patent: 3534041 (1970-10-01), van der Burg
patent: 3912743 (1975-10-01), Christensen et al.
patent: 4007196 (1977-02-01), Christensen et al.
patent: 4046889 (1977-09-01), Ondetti et al.
patent: 4062848 (1977-12-01), van der Burg
patent: 4085225 (1978-04-01), Welle et al.
patent: 4129225 (1978-12-01), Bailey
patent: 4136193 (1979-01-01), Bogeso et al.
patent: 4154960 (1979-05-01), Ondetti et al.
patent: 4172074 (1979-10-01), Eriksoo et al.
patent: 4194009 (1980-03-01), Molloy et al.
patent: 4314081 (1982-02-01), Molloy et al.
patent: 4337201 (1982-06-01), Petrillo, Jr.
patent: 4338317 (1982-07-01), Temple, Jr. et al.
patent: 4344949 (1982-08-01), Hoefle et al.
patent: 4410520 (1983-10-01), Watthey
patent: 4478836 (1984-10-01), Mouzin et al.
patent: 4536518 (1985-08-01), Welch, Jr. et al.
patent: 4587258 (1986-05-01), Gold et al.
patent: 4761501 (1988-08-01), Husbands et al.
patent: 4956388 (1990-09-01), Robertson et al.
patent: 5138069 (1992-08-01), Carini et al.
patent: 5399578 (1995-03-01), Buhlmayer et al.
patent: 5591762 (1997-01-01), Hauel et al.
patent: 6187752 (2001-02-01), Sudilovsky et al.
patent: 6194460 (2001-02-01), Dicpinigaitis
patent: 7045636 (2006-05-01), Palani et al.
patent: 2004/0122051 (2004-06-01), Pratt
patent: 2005/0119248 (2005-06-01), Buntinx
patent: 2005/0171098 (2005-08-01), Clader et al.
patent: 0 432 856 (1991-06-01), None
patent: WO00/76499 (2000-12-01), None
patent: WO 2004/002461 (2004-01-01), None
patent: WO 2004/002461 (2004-01-01), None
patent: WO2004/014911 (2004-02-01), None
patent: WO 2004/045592 (2004-06-01), None
patent: WO 2004/045592 (2004-06-01), None
patent: WO2005/113518 (2005-12-01), None
patent: WO2006/044648 (2006-04-01), None
patent: WO2007/030697 (2007-03-01), None
patent: WO 2007/047978 (2007-04-01), None
patent: WO 2007/047978 (2007-04-01), None
patent: WO 2007/053596 (2007-05-01), None
Ohrui et al., Neurology, 2004, vol. 63, pp. 1324-1325.
Rogers et al., Neurology, 1998, vol. 50, pp. 136-145.
Becker, et al. “An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression”,J. Med. Chem. (2006) 49(11):3116-3135.
Beer, et al. “DOV 216,303, a “triple” reuptake inhibitor: safety, tolerability, and pharmacokinetic profile”,J. Clin Pharmacol.(2004) 44(12):1360-1370.
Bo, Dal, et al. “Assay of zofenopril and its active metabolite zofenoprilat by liquid chromatography coupled with tandem mass spectrometry”,J. Chromatogr B. Biomed Sci Appl. (2000) 749(2):287-94.
Bohme, et al. “In vitro and in vivo characterization of TC-1827, a novel brain α4β2 nicotinic receptor agonist with pro-cognitive activity”Drug Development Research(2004) 62(1):26-40.
Bonk, et al. Novel high-affinity photactivatable antagonists of corticotrophin-releasing factor (CRF) (2000)Eur. J. Biochem. 267:3017-3024.
Brown, Jason, et al. “Enriched environment and physical activity stimulate hippocampal but not olfactory bulb neurogenesis”,Eur J Neurosci. (2003) 17(10):2042-2046.
Cameron, H.A., et al. “Adult neurogenesis is regulated by adrenal steroids in the dentate gyrus”,Neuroscience(1994) 61(2):203-209.
Cushman, D.W., et al. “Differentiation of Angiotensin-Converting Enzyme (ACE) Inhibitors by Their Selective Inhibition of ACE in Physiologically Important Target Organs”,American Journal of Hypertension(1989) 2:294-306.
Edmonds-Alt, et al. “Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist”,Can J. Physiol Pharmacol.(2002) 80(5):482-488.
Eisch, Amelia, J., et al. “Drug dependence and addiction II: Adult neurogenesis and drug addiction”,Am J Psychiatry(2004) 161(3):426.
Gage, F.H., et al. “Adult brain neurogenesis and psychiatry: a novel theory of depression”,Molecular Psychiatry. (2000) 5(3):262-269.
Gould, Elizabeth, et al. “Neurogenesis in the neocortex of adult primates”,Science. (1999) 286(5439):548-552.
Hankey, Graeme J., et al. “Angiotensin-Converting Enzyme Inhibitors for Stroke Prevention—Is There Hope3 for Progress After Life?”,Stroke(2003) 34:354-356.
Hashimoto “Glycine transporter inhibitors as therapeutic agents for schizophrenia”,Recent Patents on CNS Drug Discover(2006) 1:43-53.
Hemming, Matthew L., et al. “Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid β-protein metabolism in mouse models of Alzheimer disease”,Neurobiology of Disease(2007) 273-281.
Kim, et al. “Identification of substituted 4-aminopiperidines and 3-aminopyrrolidines as potent MCH-R1 antagonists for the treatment of obesity”Bioorg Med. Chem. Lett(Jul. 29, 2006).
Kuhn, H. George, et al. “Neurogenesis in the gentate gyrus of the adult rat: Age-related decrease neuronal progenitor proliferation”,Neurosci. (1996) 16(6):2027-2033.
Lou, Min, et al. “Sustained Blockade of Brain AT1 Receptors Before and After Focal Cerebral Ischemia Alleviates Neurologic Deficits and Reduces Neuronal Injury, Apoptosis, and Inflammatory Responses in the Rat”,Journal of Cerebral Blood Flow&Metabolism(2004) 24:536-547.
Malberg, Jessica E., et al. “Chronic antidepressant increases neurogenesis in adult rat hippocampus”,J Neurosci. (2000) 20(24):9104-9110.
Mazurov, et al. “Selective alpha7 nicotinic acetylcholine receptor ligands”,Curr. med. Chem.(2006) 13(13:1567-1584.
McEwen, Bruce S., et al. “Hippocampal remodeling and damage by corticosteroids: Implications for mood disorders”,Neuropsychopharmacology. (1999) 21(4):474-84.
Mizuno, et al. “The stimulation of beta(3)-adrenoceptor causes phosphorylation of extracellular signal-regulated kinases 1 and 2 through a G(s)-but not G(i)-dependent pathway in 3T3-L1 adipocytes”,Eur. J. Phamacol.(2000) 404(102):63-68)
Onoyama, Kaoru, et al. “Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states”,Clin. Pharmacol. Ther.(1985) 38(4):462-468.
Patchett, A.A., et al. “A new claims of angiotensin-converting enzyme inhibitors”,Nature(1980) 288, 280-283.
Popik, et al. “Pharmacological Profile of the “Triple” Monamine Neurotransmiter Uptake Inhibitor< DOV 102,677”,Cell Mol Neurobiol(2006) 4/25.
Reardon, K.A., et al. “The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease”,Aust NZ J Med(2000) 30:48-53.
Santarelli, Luca, et al. “Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants”,Science. (2003) 301(5634):805-809.
Schulz, et al. “CP-154,526: a potent and selective nonpeptide antagonist of corticotrophin releasing factor receptors”,Proc Natl Acad Sci USA(1996) 93(19):10477-82.
Skolnick, et al. “Antidepressant-like actions of DOV 21,947: a “triple” reuptake inhibitor”,Eur. J. Pharmacol.(2003) 461(2-3):99-104.
Suh, et al. “Angiotensin-converting enzyme inhibitors. New orally active antihypertensive (mercaptoalkanoyl)- and [(acylthio)alkanoyl]glycine derivatives”,J. Med Chem.(1985) 28(1):57-66.
van Praag, Henriette, et al. “Running enhances neurogenesis, learning and long-term potentiation in mice”,Proc Natl Acad Sci U S A. (1999) 96(23):13427-13431.
Takata, Y, et al. “A Comparison of the Activity of the Angiotensin Converting Enzyme Inhibitors SQ 14 225, SA 446, and MK
Barlow Carrolee
Carter Todd A.
Lorrain Kym I.
Treuner Kai
Anderson James D
BrainCells Inc.
Polansky Gregg
Sughrue & Mion, PLLC
LandOfFree
Neurogenesis by modulating angiotensin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neurogenesis by modulating angiotensin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neurogenesis by modulating angiotensin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4197943